Header Logo

Connection

Ravindre Panchia to Male

Back to Details
This is a "connection" page, showing publications Ravindre Panchia has written about Male.
Ravindre Panchia
Connection Strength
0,562
Male
  1. Bisexuality among Men who have Sex with Men in Sub-Saharan Africa: Findings from the HPTN 075 Study. AIDS Behav. 2025 Mar; 29(3):747-759.
    View in: PubMed
    Score: 0,026
  2. Interest in Oral Pre-exposure Prophylaxis Among Men Who Have Sex with Men and Transfeminine Persons in HPTN 075, a Multi-center HIV Prevention Study in Sub-Saharan Africa (2015-2017). AIDS Behav. 2025 Feb; 29(2):411-419.
    View in: PubMed
    Score: 0,026
  3. Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075. AIDS Behav. 2024 Jul; 28(7):2361-2377.
    View in: PubMed
    Score: 0,025
  4. Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052. Int J STD AIDS. 2021 11; 32(13):1204-1211.
    View in: PubMed
    Score: 0,020
  5. Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study. Clin Infect Dis. 2021 07 01; 73(1):60-67.
    View in: PubMed
    Score: 0,020
  6. Likely clinical depression and HIV-related decline in antiretroviral therapy untreated women who seroconverted during participation in microbicide trials in sub-Saharan Africa. Int J STD AIDS. 2021 06; 32(7):620-628.
    View in: PubMed
    Score: 0,020
  7. HIV incidence in a multinational cohort of men and transgender women who have sex with men in sub-Saharan Africa: Findings from HPTN 075. PLoS One. 2021; 16(2):e0247195.
    View in: PubMed
    Score: 0,020
  8. Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. Int J Infect Dis. 2021 Mar; 104:465-470.
    View in: PubMed
    Score: 0,020
  9. The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075). J Int AIDS Soc. 2020 10; 23 Suppl 6:e25600.
    View in: PubMed
    Score: 0,019
  10. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531.
    View in: PubMed
    Score: 0,019
  11. Healthcare-related stigma among men who have sex with men and transgender women in sub-Saharan Africa participating in HIV Prevention Trials Network (HPTN) 075 study. AIDS Care. 2020 08; 32(8):1052-1060.
    View in: PubMed
    Score: 0,019
  12. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481.
    View in: PubMed
    Score: 0,019
  13. HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. PLoS One. 2019; 14(5):e0217501.
    View in: PubMed
    Score: 0,018
  14. Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. AIDS Behav. 2019 Jan; 23(1):289-294.
    View in: PubMed
    Score: 0,017
  15. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
    View in: PubMed
    Score: 0,017
  16. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. AIDS. 2018 06 19; 32(10):1301-1306.
    View in: PubMed
    Score: 0,017
  17. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr. 2018 04 15; 77(5):484-491.
    View in: PubMed
    Score: 0,016
  18. Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):388-393.
    View in: PubMed
    Score: 0,016
  19. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One. 2017; 12(5):e0177281.
    View in: PubMed
    Score: 0,015
  20. Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017 05; 18(3):100-109.
    View in: PubMed
    Score: 0,015
  21. Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa. Trans R Soc Trop Med Hyg. 2017 03 01; 111(3):132-136.
    View in: PubMed
    Score: 0,015
  22. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2017 Jan 01; 74(1):112-116.
    View in: PubMed
    Score: 0,015
  23. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 09 01; 375(9):830-9.
    View in: PubMed
    Score: 0,014
  24. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 07 01; 72(3):304-9.
    View in: PubMed
    Score: 0,014
  25. Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. J Acquir Immune Defic Syndr. 2015 Oct 01; 70(2):212-7.
    View in: PubMed
    Score: 0,014
  26. Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):138-44.
    View in: PubMed
    Score: 0,013
  27. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
    View in: PubMed
    Score: 0,013
  28. CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention. PLoS One. 2014; 9(3):e90754.
    View in: PubMed
    Score: 0,012
  29. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
    View in: PubMed
    Score: 0,012
  30. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0,012
  31. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,012
  32. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21; 31(5):777-83.
    View in: PubMed
    Score: 0,011
  33. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011 Sep; 15(9):1194-200, i.
    View in: PubMed
    Score: 0,010
  34. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.